Foghorn Swings to $58.2M Q3 Profit on $74.1M Catch-Up Adjustment, Cash Runway to 2029
FHTX is trading near its 52-week low of $1.79 (4.5% above the low).
Summary
Foghorn posted Q3 collaboration revenue of $83.5M and EPS of $0.80, swinging to $58.2M of net income from a loss a year earlier. The profit is almost entirely accounting: a $74.1M cumulative catch-up adjustment tied to updated estimated future costs for the discontinued Lilly programs, not new cash coming in. The real substance is the balance sheet — $156M in cash funds operations into the second half of 2029, a long runway for a company trading near its 52-week low. R&D and G&A fell year over year on lower partnered-program, personnel and facilities costs after the October restructuring that cut 40% of the workforce. Pipeline milestones ahead: dose-range finding studies for the IBD program start in Q4 2026, first-in-human IBD trials are targeted by end of 2027, and an IND for the EP300 degrader is planned for 2027.
At the time of this announcement, FHTX was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.1M. The 52-week trading range was $1.79 to $7.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.